US Stock Market Movement: Tempus AI Surges on September 24 with Data Renewal, Zacks Buy Rating, and Medical AI Momentum

Tempus AI Major Surge Analysis on September 24

Keywords: data renewal, Zacks buy rating, medical AI

1. On September 24, institutions included Tempus AI in the list of recommended medical AI stocks and assigned it a Zacks Rank "#2 Buy". The company mainly engages in precision medicine, genetic testing, and medical data analysis.

2. On September 21, Tempus AI extended its data partnership with Recursion Pharmaceuticals until November 2029, with a total payment commitment of $42 million over the next three years. Tempus AI also secured a global non-exclusive license for its RNA foundational model TxFM, strengthening data licensing and AI-driven drug development business lines.

3. On September 11, the company launched a multi-year whole genome research platform, aiming to generate 100,000 whole genome datasets linked to clinical, imaging, pathology, and treatment outcomes, with a long-term goal of expanding to 1 million datasets. This will provide a data foundation for AI-driven medical research and personalized treatment.

(Disclaimer: This content is a summary generated by AI technology from publicly available information and is for reference only. It does not constitute investment advice.)